Benjamin Hohl Sells 1,000 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 1,000 shares of the stock in a transaction dated Monday, March 24th. The stock was sold at an average price of $22.50, for a total transaction of $22,500.00. Following the sale, the chief financial officer now owns 23,000 shares of the company’s stock, valued at approximately $517,500. This represents a 4.17 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Benjamin Hohl also recently made the following trade(s):

• On Thursday, February 27th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $20.41, for a total value of $66,332.50.
• On Wednesday, February 5th, Benjamin Hohl sold 1,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $22.52, for a total value of $22,520.00.
• On Monday, January 27th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $21.59, for a total value of $70,167.50.
• On Friday, January 3rd, Benjamin Hohl sold 1,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $25.04, for a total value of $25,040.00.
• On Monday, December 30th, Benjamin Hohl sold 900 shares of Enliven Therapeutics stock. The shares were sold at an average price of $22.51, for a total transaction of $20,259.00.
• On Friday, December 27th, Benjamin Hohl sold 3,350 shares of Enliven Therapeutics stock. The stock was sold at an average price of $22.15, for a total transaction of $74,202.50.

Enliven Therapeutics Price Performance

NASDAQ:ELVN opened at $20.58 on Thursday. The firm’s 50-day moving average price is $21.29 and its 200-day moving average price is $23.76. The company has a market capitalization of $1.01 billion, a PE ratio of -10.83 and a beta of 1.04. Enliven Therapeutics, Inc. has a 1-year low of $15.96 and a 1-year high of $30.03.

Enliven Therapeutics (NASDAQ:ELVN) last announced its quarterly earnings data on Thursday, March 13th. The company reported ($0.46) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.07. The business had revenue of $0.03 million during the quarter. Equities analysts anticipate that Enliven Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently issued reports on ELVN shares. BTIG Research started coverage on shares of Enliven Therapeutics in a research report on Friday, December 13th. They set a “buy” rating and a $42.00 price target on the stock. HC Wainwright upped their target price on Enliven Therapeutics from $37.00 to $39.00 and gave the stock a “buy” rating in a report on Friday, March 21st. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $38.75.

Institutional Trading of Enliven Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in ELVN. Tower Research Capital LLC TRC raised its stake in Enliven Therapeutics by 230.2% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company’s stock valued at $36,000 after buying an additional 1,114 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new position in shares of Enliven Therapeutics in the 4th quarter worth about $97,000. BNP Paribas Financial Markets bought a new position in Enliven Therapeutics in the 4th quarter worth about $112,000. ExodusPoint Capital Management LP purchased a new stake in Enliven Therapeutics during the 4th quarter valued at about $200,000. Finally, Brevan Howard Capital Management LP purchased a new stake in Enliven Therapeutics during the 4th quarter valued at about $228,000. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.